Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

ObjectiveMacrophage activation syndrome (MAS) is a life-threatening, potentially fatal condition associated with systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of sJIA MAS. Many cases of MAS are medically refractory to traditional doses of b...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mikhail M. Kostik, Eugenia A. Isupova, Konstantin Belozerov, Tatyana S. Likhacheva, Evgeny N. Suspitsin, Rinat Raupov, Vera V. Masalova, Irina A. Chikova, Margarita F. Dubko, Olga V. Kalashnikova, Vyacheslav G. Chasnyk, Randy Q. Cron
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-07-01
coleção:	Frontiers in Pediatrics
Assuntos:	canakinumab interleukin-1 macrophage activation syndrome monoclonal antibody dosing systemic juvenile idiopathic arthritis
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fped.2022.894846/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!